ice water test distinguishes clinical bladder hypersensitivity from overactivity disorders.BMC Urol,2006,6:31 14.Sand P,Zinner N,Newman D,Lucente V,Dmochowski R,Kelleher C,Dahl NV. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder:a multicentre,community-based,randomized study.BJU Int, 2007,99:836-844 15.Song C,Park JT,Heo KO,Lee KS,Choo MS.Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome:a prospective, randomized study.J Korean Med Sci,2006,21:1060-1063 16.Andersson KE.Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms.Int JClinPract Suppl,2006 Dec,151:8-16 17.Fader M.Glickman S,Haggar V,Barton R.Brooks R,Malone-Lee J.Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity:a double-blind,randomized crossover trial.J Urol,2007,177:208-13:discussion 213 18.Babu R.Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Indian Pediatr,2006,43:980-983 19.Walter U,Dressler D.Wolters A.Wittstock M.Benecke R.Overactive bladder in Parkinson's disease:alteration of brainstem raphe detected by transcranial sonography.Eur J Neurol,2006,13:1291-1297 20.Wang AC,Chih SY,Chen MC.Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency:a randomized placebo-controlled trial.Urology,2006,68:999-1004 21.Brading AF.Acetylcholine and the overactive bladder.Eur Urol,2007,51:881-883 22.Sui GP.Wu C.Severs N.Newgreen D,Fry CH.The association between T-type Ca current and outward current in isolated human detrusor cells from stable and overactive bladders.BJU Int,2007,99:436-441 23.Leng WW,Morrisroe SN.Sacral nerve stimulation for the overactive bladder.Urol C1 in North Am,2006,33:491-501 24.Philip J,Willmott S,Owen D,Samsudin C,Irwin PP.A double-blind,randomizedice water test distinguishes clinical bladder hypersensitivity from overactivity disorders. BMC Urol, 2006, 6:31 14. Sand P, Zinner N, Newman D, Lucente V, Dmochowski R, Kelleher C, Dahl NV. Oxybutynin transdermal system improves the quality of life in adults with overactive bladder: a multicentre, community-based, randomized study. BJU Int, 2007, 99:836-844 15. Song C, Park JT, Heo KO, Lee KS, Choo MS. Effects of bladder training and/or tolterodine in female patients with overactive bladder syndrome: a prospective, randomized study. J Korean Med Sci, 2006, 21:1060-1063 16. Andersson KE. Treatment-resistant detrusor overactivity--underlying pharmacology and potential mechanisms. Int J Clin Pract Suppl, 2006 Dec,151:8-16 17. Fader M, Glickman S, Haggar V, Barton R, Brooks R, Malone-Lee J. Intravesical atropine compared to oral oxybutynin for neurogenic detrusor overactivity: a double-blind, randomized crossover trial. J Urol, 2007,177:208-13; discussion 213 18. Babu R. Effectiveness of tolterodine in nonneurogenic voiding dysfunction. Indian Pediatr, 2006,43:980-983 19. Walter U, Dressler D, Wolters A, Wittstock M, Benecke R. Overactive bladder in Parkinson's disease: alteration of brainstem raphe detected by transcranial sonography. Eur J Neurol, 2006,13:1291-1297 20. Wang AC, Chih SY, Chen MC. Comparison of electric stimulation and oxybutynin chloride in management of overactive bladder with special reference to urinary urgency: a randomized placebo-controlled trial. Urology, 2006, 68:999-1004 21. Brading AF. Acetylcholine and the overactive bladder. Eur Urol, 2007,51:881-883 22. Sui GP, Wu C, Severs N, Newgreen D, Fry CH. The association between T-type Ca2+ current and outward current in isolated human detrusor cells from stable and overactive bladders. BJU Int, 2007,99:436-441 23. Leng WW, Morrisroe SN. Sacral nerve stimulation for the overactive bladder. Urol Clin North Am, 2006, 33:491-501 24. Philip J, Willmott S, Owen D, Samsudin C, Irwin PP. A double-blind, randomized